Figure 3From: Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosisRenal tumor recurrence in mice treated with either RAD001 or NVP-BEZ235 8 weeks after coming off drug. A-C. Dot plot analysis of gross kidney tumor score (A), microscopic kidney tumor score (B), and percent cellularity of each lesion (C) in ENU-treated Tsc2+- mice at age 32 weeks that received either 1) no treatment, 2) RAD001 10 mg/kg PO 5 d/week, or 3) NVP-BEZ235 45 mg/kg PO QD; all for four weeks from age 20 – 24 weeks. A, B: Each dot represents a mouse kidney. C: Each dot represents a mouse kidney cystadenoma. A, p = .002; B and C, p NS; by Kruskal-Wallis test.Back to article page